ABO2013 / Suzhou Abogen Biosci - LARVOL DELTA

A novel EGFR neoantigen-specific mRNA cancer vaccine demonstrates immunogenicity and anti-tumor efficacy in human (AACR 2025) - P=N/A | "Notably, robust neoantigen-specific immune responses were detected with patients achieving complete remission or partial response, respectively. ABO2013, as a monotherapy and in combination with sintilimab, has exhibited a favorable safety profile and a robust neoantigen-specific immune response and promising antitumor activity, warranting further investigation in EGFR-mutated NSCLC population."

Clinical • IO biomarker • Tumor-specific neoantigens • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR